The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

AUGMENT: Is the combination of lenalidomide & rituximab efficacious in elderly patients with iNHL?

Dec 12, 2019

During the 61 stAmerican Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Marek Trněný, Charles University Hospital, Prague, CZ. We asked: AUGMENT trial: Is the combination of lenalidomide and rituximab efficacious in elderly patients with indolent non-Hodgkin lymphoma?

Marek Trněný gives an overview of the AUGMENT study design and results of the post-hoc analysis of the data in the elderly population. He concludes that the combination is safe and offers clinical benefit to older patients, especially those with follicular lymphoma.

AUGMENT: Is the combination of lenalidomide & rituximab efficacious in elderly patients with iNHL?